What Is Menopause? Symptoms, Stages, Diagnosis, and Treatment Explained

What Exactly Is Menopause?

Menopause is a single point in time, not a prolonged phase. A woman has reached menopause when she has gone exactly 12 consecutive months without a menstrual period, with no other medical cause to explain the absence. After that 12-month mark, she is said to be postmenopausal for the rest of her life.

The biological driver is the exhaustion of functional ovarian follicles. As follicle count drops below a critical threshold, the ovaries can no longer sustain adequate production of estradiol (the dominant form of estrogen) or progesterone. The hypothalamus and pituitary gland respond by sharply elevating follicle-stimulating hormone (FSH) in an attempt to stimulate the ovaries. This failed feedback loop is why a serum FSH above 40 IU/L on two separate draws, taken at least 4 to 6 weeks apart, serves as a supporting laboratory marker for menopause in women with an intact uterus and ovaries. The Menopause Society 2023 position statement notes that laboratory testing is generally unnecessary in women over 45 who present with classic symptoms and 12 months of amenorrhea.

Why "Menopause" Is Often Confused with "Perimenopause"

The term menopause is frequently misapplied to the entire multi-year transition period leading up to the final period. That transition is correctly called perimenopause (discussed in depth below). Menopause itself is a retrospective diagnosis: you can only confirm it after the 12-month amenorrhea window has closed.

Natural vs. Surgical Menopause

Natural menopause unfolds gradually over years. Surgical menopause, by contrast, is immediate. Bilateral oophorectomy (removal of both ovaries) causes an abrupt drop in estrogen within 24 to 48 hours, producing more severe and sudden vasomotor symptoms than natural menopause. A 2016 cohort study published in JAMA found that women who underwent bilateral oophorectomy before age 45 without subsequent estrogen therapy had significantly higher all-cause mortality, cardiovascular disease, and cognitive decline compared with women who retained their ovaries.

The Three Stages: Perimenopause, Menopause, and Postmenopause

Understanding the three stages clarifies why symptoms often start years before a woman's last period and why treatment decisions differ at each stage.

Perimenopause

Perimenopause begins when ovarian function starts to fluctuate, typically in a woman's mid-to-late 40s, though it may start in the early 40s. The average duration is 4 to 8 years, but it can last as few as 2 years or as many as 10. Estradiol levels swing unpredictably during this phase. FSH rises but erratically, which means a single normal FSH result does not rule out perimenopause.

Menstrual cycles become irregular first. A change in cycle length of more than 7 days in either direction from the usual pattern is the earliest recognized marker, according to the Stages of Reproductive Aging Workshop (STRAW+10) criteria published in Fertility and Sterility. Hot flashes, disrupted sleep, and mood changes often begin during late perimenopause, when periods may be skipping for 60 days or longer at a stretch.

Pregnancy remains possible during perimenopause. Ovulation still occurs sporadically, which means contraception should be continued until menopause is confirmed.

Menopause

As defined above: 12 consecutive months without a period. The final menstrual period (FMP) typically occurs around age 51 in U.S. Women. Data from the Study of Women's Health Across the Nation (SWAN), which followed 3,302 women across multiple ethnic groups, found that the median age at the FMP was 51.4 years, with Black women reaching menopause slightly earlier (median 49.3 years) and Japanese-American women slightly later (median 52.4 years) compared with white women (median 51.8 years) Swan Study, published in the American Journal of Epidemiology, available via PubMed.

Postmenopause

Every year after the FMP is postmenopause. Estrogen levels stabilize at a chronically low level, primarily sourced from peripheral conversion of adrenal androgens into estrone (a weaker estrogen). The health risks associated with low estrogen, including osteoporosis, cardiovascular disease, and urogenital atrophy, accumulate during this phase. Postmenopause has no defined end point; a woman remains postmenopausal for the rest of her life.

Symptoms of Menopause: What to Expect

Menopause affects multiple organ systems simultaneously. Symptoms vary widely in severity, partly due to genetic factors, body composition, ethnicity, and lifestyle.

Vasomotor Symptoms (Hot Flashes and Night Sweats)

Hot flashes affect roughly 75 to 80% of menopausal women in Western populations, according to data compiled by the North American Menopause Society. A hot flash is a sudden sensation of intense warmth spreading over the chest, neck, and face, lasting 1 to 5 minutes and often followed by sweating and chilling. Night sweats are hot flashes that occur during sleep, disrupting sleep architecture and contributing to fatigue.

For most women, vasomotor symptoms peak in late perimenopause and the first 2 years of postmenopause. However, the Penn Ovarian Aging Study found that 42% of women still experienced frequent hot flashes 7 to 10 years after their FMP, demonstrating that symptoms do not always resolve quickly Penn Ovarian Aging Study results at PubMed.

Genitourinary Syndrome of Menopause (GSM)

GSM is the preferred clinical term for vaginal dryness, vulvovaginal atrophy, dyspareunia (painful intercourse), urinary urgency, and recurrent urinary tract infections caused by low estrogen. Unlike hot flashes, GSM does not improve on its own over time. It tends to worsen progressively without treatment. Approximately 50% of postmenopausal women experience GSM symptoms, yet fewer than 25% discuss it with a clinician, according to a survey published in Menopause (the journal of the Menopause Society).

Mood, Cognition, and Sleep

Estrogen modulates serotonin and norepinephrine pathways. Declining estrogen during perimenopause is associated with increased depressive symptoms, irritability, and anxiety, even in women with no prior psychiatric history. A prospective study in the Archives of General Psychiatry (JAMA Network) found that women in the menopausal transition had a two-fold higher risk of a major depressive episode compared with premenopausal women.

Sleep disruption, often tied to night sweats, compounds mood changes. Cognitive complaints such as word-finding difficulty and reduced concentration are common and generally improve after the transition stabilizes.

Bone Loss

Estrogen suppresses osteoclast activity. After menopause, osteoclasts (the cells that break down bone) become more active relative to osteoblasts (cells that build bone), producing a net loss of bone mineral density (BMD). Women may lose 1 to 3% of BMD per year in the first 5 to 7 years after their FMP. A fracture risk assessment using the FRAX tool, combined with a dual-energy X-ray absorptiometry (DXA) scan, is recommended for postmenopausal women by the U.S. Preventive Services Task Force to screen for osteoporosis.

Cardiovascular Changes

Before menopause, estrogen has a favorable effect on LDL cholesterol, HDL cholesterol, and endothelial function. After the FMP, LDL rises, HDL falls, and central adiposity tends to increase. The American Heart Association has recognized menopause as a female-specific risk factor for cardiovascular disease in its 2020 guidelines on sex-specific cardiovascular risk.

How Is Menopause Diagnosed?

Diagnosis is primarily clinical. In women over 45 with classic symptoms and 12 months of amenorrhea, no laboratory testing is required for confirmation.

When Lab Testing Is Useful

FSH measurement is most useful in women under 45, women who have undergone hysterectomy (no periods to track), women on hormonal contraception that suppresses cycles, and women presenting with atypical symptoms. An FSH above 40 IU/L on two samples taken 4 to 6 weeks apart supports a diagnosis of menopause in the right clinical context. Estradiol levels below 30 pg/mL are consistent with menopause but are not independently diagnostic.

Ruling Out Other Causes of Amenorrhea

Before attributing amenorrhea to menopause, clinicians should rule out pregnancy, thyroid dysfunction (TSH testing), hyperprolactinemia, and premature ovarian insufficiency (POI) in younger women. POI, defined as ovarian dysfunction before age 40 with FSH above 40 IU/L and oligomenorrhea for at least 4 months, is distinct from natural menopause and carries different management implications. The European Society of Human Reproduction and Embryology (ESHRE) guideline on POI recommends hormone therapy until the natural age of menopause for women diagnosed with POI, given the risks of long-term estrogen deficiency.

Evidence-Based Treatments for Menopause

Treatment is not mandatory, but it is evidence-based and effective for a range of menopause-related conditions. Options span from hormone therapy to non-hormonal medications to lifestyle interventions.

Menopausal Hormone Therapy (MHT / HRT)

Hormone therapy remains the most effective treatment for vasomotor symptoms and GSM. The Menopause Society 2023 Position Statement states: "For women aged younger than 60 years or within 10 years of menopause onset who do not have contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture." The full statement is available at the Menopause Society website.

Estrogen-only therapy is appropriate for women who have had a hysterectomy. Women with an intact uterus require the addition of a progestogen to protect the endometrium from estrogen-driven hyperplasia. Options include oral micronized progesterone (Prometrium), medroxyprogesterone acetate (Provera), or the levonorgestrel-releasing intrauterine system.

The Women's Health Initiative (WHI) randomized 16,608 postmenopausal women aged 50 to 79 to conjugated equine estrogen plus medroxyprogesterone acetate versus placebo. The 2002 publication in JAMA initially raised concerns about breast cancer and cardiovascular risk. Subsequent reanalysis by age group clarified that the increased risks applied primarily to women who initiated therapy more than 10 years after menopause or over age 60, a concept now known as the "timing hypothesis" or "window of opportunity." Women aged 50 to 59 who received estrogen-alone in WHI actually had a significantly reduced risk of myocardial infarction and all-cause mortality.

Routes of administration matter. Transdermal estradiol (patches, gels, sprays) delivers estrogen directly into circulation, bypassing hepatic first-pass metabolism and producing lower triglyceride levels and lower risk of venous thromboembolism compared with oral estrogen. A 2008 case-control study in the BMJ found that transdermal estradiol was not associated with increased VTE risk, while oral estrogen was.

Non-Hormonal Pharmacotherapy

For women who cannot or choose not to use hormone therapy, several non-hormonal options have demonstrated efficacy:

• Fezolinetant (Veozah): A selective neurokinin 3 receptor antagonist approved by the FDA in May 2023 specifically for moderate-to-severe vasomotor symptoms. In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg reduced hot flash frequency by 63% from baseline at week 12 versus 45% for placebo (P<0.001). FDA approval information is available at the FDA website.
• Paroxetine mesylate 7.5 mg (Brisdelle): The only FDA-approved SSRI for vasomotor symptoms. It reduces hot flash frequency by approximately 33 to 67% in clinical trials.
• Venlafaxine 75 mg, escitalopram 10 to 20 mg, and gabapentin 300 mg three times daily have supporting evidence from randomized controlled trials, though none carry an FDA indication specifically for menopause.

Local Estrogen for GSM

Low-dose vaginal estrogen (cream, ring, or tablet/suppository) treats GSM effectively with minimal systemic absorption. The FDA-approved options include vaginal estradiol cream (Estrace), the estradiol vaginal ring (Estring), and vaginal estradiol tablets (Vagifem/Yuvafem). Because systemic absorption is very low at these doses, local vaginal estrogen is generally considered safe even in breast cancer survivors, though oncologist review is advised. The ACOG Clinical Practice Guideline on Genitourinary Syndrome of Menopause endorses low-dose vaginal estrogen as a first-line treatment.

Lifestyle Modifications

No pharmaceutical intervention replaces lifestyle. Weight-bearing exercise reduces bone loss and may reduce hot flash severity. A randomized trial in Maturitas showed that women who increased physical activity to 3.5 hours per week had significantly fewer moderate-to-severe hot flashes after 24 weeks compared with sedentary controls. Maintaining a BMI below 30, reducing alcohol, and stopping smoking all reduce cardiovascular risk and may reduce hot flash frequency.

Premature Menopause and Premature Ovarian Insufficiency

Premature menopause (before age 40) affects approximately 1% of women. POI is not simply early menopause: ovarian function may return sporadically, and spontaneous pregnancy remains possible in 5 to 10% of cases. The long-term consequences of estrogen deficiency starting at a younger age are more pronounced, with greater cumulative risks of cardiovascular disease, osteoporosis, cognitive decline, and Parkinson's disease. Hormone therapy initiated promptly and continued until at least the average age of natural menopause (51) is the standard recommendation from both The Menopause Society and the ESHRE POI guideline.

Menopause and Long-Term Health: What the Evidence Shows

Bone Health

The 10-year fracture risk in postmenopausal women without treatment can be substantial. Data from the National Osteoporosis Foundation (via NIH) indicate that one in two women over age 50 will experience an osteoporosis-related fracture in their lifetime. Hormone therapy reduces vertebral fracture risk by approximately 33% and hip fracture risk by 25 to 30% in randomized trials, even in women not selected for osteoporosis.

Cardiovascular Health

Estrogen maintains endothelial nitric oxide production and favorable lipid profiles. A 2016 meta-analysis in Climacteric found that hormone therapy initiated in younger postmenopausal women (under 60 or within 10 years of menopause) reduced coronary heart disease risk by approximately 30% compared with placebo. The American Heart Association's 2020 statement on menopause and cardiovascular disease underscores that the timing of initiation is the critical variable.

Cognitive Function

Estrogen has neuroprotective properties, including effects on synaptic density and amyloid clearance. The timing hypothesis also applies to cognition: initiating estrogen therapy during perimenopause or early postmenopause may reduce Alzheimer's disease risk, while initiating it after age 65 may not confer benefit or could be harmful. A 2017 review in JAMA Neurology summarized evidence from multiple cohorts supporting the critical window concept for cognitive protection.

When to See a Clinician

A woman should discuss menopause with a clinician if:

• Hot flashes or night sweats are disrupting daily function or sleep.
• She is younger than 45 and experiencing missed periods or hot flashes.
• Vaginal dryness or painful intercourse is affecting quality of life.
• She has questions about fracture risk or wants a DXA scan.
• She is considering starting, adjusting, or stopping hormone therapy.

The Menopause Society maintains a directory of certified menopause practitioners at menopause.org.

Women who begin hormone therapy typically see vasomotor symptom reduction within 4 to 8 weeks of reaching a therapeutic dose. If symptoms are not adequately controlled after 8 to 12 weeks, dose adjustment or a change in formulation is appropriate before concluding that HRT is ineffective.